Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. News
  7. Summary
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

FDA Grants Fast Track Designation for Eryaspase in Hypersensitive All of Erytech Pharma S.A

07/30/2021 | 10:09am EDT

ERYTECH Pharma announced that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase). Asparaginase has been an integral component of ALL treatment for several years but is associated with treatment-limiting hypersensitivity in up to 30% of patients. Discontinuation of asparaginase therapy in ALL patients has been associated with inferior event free survival, highlighting the need for additional asparaginase based treatment options. In December 2020, positive results from a Phase 2 trial evaluating the safety and enzyme activity of eryaspase in primarily pediatric ALL patients who developed hypersensitivity reactions to pegylated asparaginase were presented by the Nordic Society of Pediatric Hematology and Oncology at the 2020 American Society of Hematology annual meeting. This data demonstrated that eryaspase, in combination with chemotherapy, administered every two weeks, provided a sustained asparaginase enzyme activity level, and was generally well tolerated with few hypersensitivity reactions. The Company recently confirmed its intention to submit a Biologics License Application (BLA) for eryaspase in this indication in the fourth quarter of 2021 pending successful completion of remaining steps. Fast Track is a program designed to facilitate the expedited development and review of a new drug, alone or in combination with other drugs, to treat serious or life threatening conditions for which there is a demonstration of the potential to address an unmet medical need. The purpose is to advance new drugs earlier for patients who need them. In April 2020, eryaspase was also granted Fast Track designation for the development of a second-line treatment of patients with metastatic pancreatic cancer. A Phase 3 trial in this indication completed enrollment in January 2021 and final results are expected in the fourth quarter of 2021.


ę S&P Capital IQ 2021
All news about ERYTECH PHARMA S.A.
09/22ERYTECH PHARMA S A : Announces the Availability of its Half-Year Financial Report 2021
AQ
09/22European ADRs Climb Higher in Wednesday Trading
MT
09/21European ADRs Move Higher in Tuesday Trading
MT
09/21ERYTECH PHARMA S A : ▪TRYbeCA-1, Phase 3 trial of eryaspase in second-line metastati..
PU
09/20ERYTECH PHARMA S A : Provides Business Update and Reports Financial Results for the First ..
AQ
09/20ERYTECH PHARMA S A : I.CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE HALF-YEAR FINANCIAL..
PU
09/20European ADRs Move Sharply Lower in Monday Trading
MT
09/17ERYTECH PHARMA S A : to Host on September 21, 2021 Second Quarter 2021 conference call and..
PU
09/15ERYTECH PHARMA S A : to Host on September 21, 2021 Second Quarter 2021 conference call and..
AQ
09/13European ADRs Rise 1% Monday as Energy Giants Gain, Pharma Retreats
MT
More news
Financials
Sales 2021 9,79 M 11,5 M 11,5 M
Net income 2021 -65,1 M -76,3 M -76,3 M
Net Debt 2021 16,1 M 18,9 M 18,9 M
P/E ratio 2021 -1,32x
Yield 2021 -
Capitalization 143 M 168 M 167 M
EV / Sales 2021 16,2x
EV / Sales 2022 5,21x
Nbr of Employees 196
Free-Float 88,9%
Chart ERYTECH PHARMA S.A.
Duration : Period :
ERYTECH Pharma S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERYTECH PHARMA S.A.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 5,15 €
Average target price 14,50 €
Spread / Average Target 182%
EPS Revisions
Managers and Directors
Gil Beyen Chief Executive Officer & Director
Eric Soyer Chief Operating & Financial Officer
Jean-Paul Kress Chairman
Iman El-Hariry Chief Medical Officer
Stewart Craig Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
ERYTECH PHARMA S.A.-27.57%168
GILEAD SCIENCES, INC.22.52%89 936
BIONTECH SE316.17%82 443
WUXI APPTEC CO., LTD.36.63%69 407
REGENERON PHARMACEUTICALS33.94%67 262
VERTEX PHARMACEUTICALS-22.03%48 202